- Home
- BVC vs ZYME Comparison
BVC vs ZYME Comparison
Compare BVC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BVC | ZYME |
|---|---|---|
| Founded | 2019 | 2003 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BVC | ZYME |
|---|---|---|
| Price | $11.35 | $26.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $38.90 |
| AVG Volume (30 Days) | 34.3K | ★ 512.3K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $0.99 | $16.00 |
| 52 Week High | $18.00 | $31.34 |
Technical Indicators
Market Signals| Indicator | BVC | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 46.46 |
| Support Level | $8.04 | $25.81 |
| Resistance Level | $11.54 | $27.30 |
| Average True Range (ATR) | 1.34 | 0.98 |
| MACD | -0.46 | -0.20 |
| Stochastic Oscillator | 0.00 | 29.22 |
Price Performance
Historical ComparisonAbout BVC BitVentures Limited American Depositary Shares
BitVentures Ltd is a technology-focused company. It is focused on developing technology businesses in verticals including e-commerce, digital assets, and other areas of consumer and enterprise technology. The company identifies and supports technology ventures across these areas.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.